Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesLudwig Kappos, Rupert Sandbrink, Chris H. Polman et al.|American Journal of Ophthalmology|2006Cited by 551
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and ProgressionAlberto Ascherio, Christoph Pohl, Ernst‐Wilhelm Radü et al.|JAMA Neurology|2014Cited by 514
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Rupert Sandbrink, Mark S. Freedman et al.|The Lancet|2007Cited by 502
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O’Connor, Timon Bogumil, Massimo Filippi et al.|The Lancet Neurology|2009Cited by 403
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Christoph Pohl, Mark S. Freedman et al.|The Lancet Neurology|2009Cited by 370